Target intelligence / Profile preview

65 kDa phosphoprotein (pp65) (pp65)

Target
pp65
Molecular classification
Viral protein, Tegument protein, Phosphoprotein, Matrix protein
01

Overview

The 65 kDa phosphoprotein (pp65), encoded by the UL83 gene, is the most abundant tegument protein of Human Cytomegalovirus (HCMV) and a critical factor in viral pathogenesis (UniProt P06725). It primarily functions as an immune modulator, subverting the host's innate immune response by inhibiting the activation of interferon regulatory factor 3 (IRF3) and the cGAS-STING pathway, thereby preventing the production of type I interferons (, 29263269). Additionally, pp65 acts as a scaffold protein during viral assembly, facilitating the incorporation of other tegument proteins into the virion. Due to its high abundance and immunodominance, pp65 is a major target for both humoral and cellular immune responses, making it a central antigen in the development of CMV vaccines and adoptive T-cell therapies. In clinical settings, the pp65 antigenemia assay is a widely used biomarker for the rapid diagnosis and monitoring of CMV infection in immunocompromised patients, such as transplant recipients. Furthermore, the expression of pp65 in certain malignancies like glioblastoma has positioned it as a novel target for cancer immunotherapy.

Other names
Phosphoprotein UL83Tegument protein UL8365 kDa matrix phosphoproteinUL83Cytomegalovirus tegument protein pp65
02

Mechanism of action

Induction of antigen-specific cellular immune responses (CD4+ and CD8+ T cells) via MHC presentation of pp65-derived peptides; experimental small molecule inhibition of pp65 phosphorylation or protein-protein interactions to disrupt viral immune evasion and assembly.

03

Biological functions

Immune evasionViral assemblyRegulation of viral gene expressionInhibition of host innate immune responseModulation of antigen presentation
04

Disease associations

Cytomegalovirus infectionCongenital cytomegalovirus infectionGlioblastomaScleroderma
05

Safety considerations

Risk of immunogenicityPotential for off-target effects in adoptive T-cell therapiesLack of standardization in antigenemia assaysViral escape through mutations in the UL83 gene
06

Interacting drugs

Triplex (vaccine)

5 more in the full profile.

07

Biomarkers

pp65 antigenemiaCMV-specific T-cell response (ELISpot)Viral load (qPCR)

Source types: Peer-reviewed publication · Government or health-agency page. Sources are available to Gosset users. Log in to see them.

Beyond the preview

Go deeper on 65 kDa phosphoprotein (pp65) (pp65).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on 65 kDa phosphoprotein (pp65) (pp65).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call